Health
Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer – OncLive
Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast…
Chau T. Dang, MD, the Regional Care Network Medical Site Director at Memorial Sloan Kettering Westchester, discusses the safety profile of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.
The 5-year results from the final analysis of the phase 2 BERENICE trial (NCT02132949), which were presented during the ESMO Breast Cancer Virtual Meeting 2021, showed that in cohort A of the study, in which patients…
-
Noosa News23 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General19 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General20 hours agoNationals Leader David Littleproud says nuclear power policy ‘sensible’ next step